Investigational drug · Phase 3
HS-10504
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic NSCLC.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "HS-10504"
First trial start
2026
Oct 23, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10504", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10504" as an intervention, largest first.
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07414953 · 400 participants (planned) · Start Mar 30, 2026 · Primary completion Apr 30, 2027
Drug: HS-10504; SHR-A2009 and 4 more · For: Lung Cancer
- A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06461156 · 230 participants (planned) · Start Jun 26, 2024 · Primary completion Dec 31, 2026
Drug: HS-10504 · For: Locally Advanced or Metastatic NSCLC
Sites: Guangzhou, China
- Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLCPivotal-lookingRecruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07754123 · 206 participants (planned) · Start Oct 23, 2026 · Primary completion Aug 31, 2028
Drug: HS-10504; platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) · For: Advanced or Metastatic NSCLC
Sites: Guangzhou, China
- A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.Not yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07836504 · 32 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 25, 2027
Drug: HS-10504 · For: To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07685041 · 24 participants (planned) · Start Jun 27, 2026 · Primary completion Nov 19, 2026
Drug: HS-10504; midazolam · For: NSCLC
- A Phase I Clinical Trial to Evaluate Pharmacokinetics of HS-10504Not yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07770217 · 18 participants (planned) · Start Aug 2, 2026 · Primary completion Sep 10, 2026
Drug: HS-10504; Rifampin · For: Healthy Participants
- A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504Not yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07764692 · 8 participants (planned) · Start Aug 1, 2026 · Primary completion Mar 1, 2027
Drug: HS-10504; Itraconazole Capsules · For: Healthy Participants
- A Mass Balance Study of [14C]HS-10504Not yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07764705 · 6 participants (planned) · Start Jul 30, 2026 · Primary completion Sep 30, 2026
Drug: [¹⁴C]HS-10504 · For: Healthy Subjects
Newest research
PubMed records naming it or its code names, newest first.
- Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024).
Nagpure NR, Patel HM · Expert Opin Ther Pat 2025
- A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Gawli CS, Patil CR, Patel HM · Bioorg Med Chem 2025
Also in development for Advanced or Metastatic NSCLC
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
- Pemetrexed and CisplatinPhase 31 trial
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Advanced or Metastatic NSCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.